お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
963494

がん/腫瘍プロファイリングの市場規模、シェア、動向分析:技術、バイオマーカータイプ、がんのタイプ、用途、地域別、2020年~2027年の予測

Cancer/Tumor Profiling Market Share, Size, Trends, Industry Analysis Report by Technology ; By Biomarker Type ; By Cancer Type; By Application; By Regions - Segment Forecast, 2020 - 2027

出版日: | 発行: Polaris Market Research | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.53円
がん/腫瘍プロファイリングの市場規模、シェア、動向分析:技術、バイオマーカータイプ、がんのタイプ、用途、地域別、2020年~2027年の予測
出版日: 2020年09月01日
発行: Polaris Market Research
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん/腫瘍プロファイリングの市場規模は、2027年には153億2000万米ドルに達すると予測されています。世界的に、毎年がん患者が増加しています。 WHOによると、この病気は2019年に2番目に多い死亡原因であると考えられています。2015年には約1,760万人のがん関連の症例があり、2018年には1,810万人に増加し、約960万人が死亡しました。患者数の増加は、同市場成長の主な要因です。

また、腫瘍と進行段階の特定にかかる時間の短縮、がん研究へのサポートを改善する認定技術、新しい治療法や薬剤設計の新たな技術の開発のための主要バイオテクノロジー企業による国を超えた大規模な投資は、大幅に市場の成長を推進しており、予測期間中のさらなる成長が期待されています。

現在、ゲノムベースの予後バイオマーカーは、臨床段階では複数の種類のがんの予後予測に利用することが可能です。しかし、変換の難しさがバイオマーカーの発見の段階とその臨床変換の間の大きな隔たりとなっています。腫瘍ゲノムデータの取得は、がんの予測、診断、治療において最も重要なステップであると考えられています。

当レポートは、世界のがん/腫瘍プロファイリング市場について調査しており、市場規模、動向や予測、トランスデューサーの周波数帯・がんのタイプ・バイオマーカー・用途・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 概要と範囲

第2章 エグゼクティブサマリー

  • 市場の定義
  • 市場セグメンテーション

第3章 市場の洞察

  • 業界のスナップショット
  • 市場力学
  • ポーターのファイブフォース分析
  • PEST分析
  • バリューチェーン分析
  • 競合ランキング分析(2019年)

第4章 市場分析:トランスデューサーの周波数帯別

  • 市場シェア(2019年および2027年)
  • イムノアッセイ
  • 次世代シーケンシング(NGS)
  • ポリメラーゼ連鎖反応(PCR)
  • インサイチュハイブリダイゼーション
  • マイクロアレイ
  • 質量分析
  • その他

第5章 市場分析:がんのタイプ別

  • 市場シェア(2019年および2027年)
  • 乳がん
  • 肺がん
  • 結腸直腸がん
  • 前立腺がん
  • 黒色腫がん
  • その他のがん

第6章 市場分析:バイオマーカータイプ別

  • 市場シェア(2019年および2027年)
  • ゲノムバイオマーカー
  • タンパク質バイオマーカー
  • その他

第7章 市場分析:用途別

  • 市場シェア(2019年および2027年)
  • 診断
  • 予後
  • 個別化医療
  • バイオマーカーの発見
  • 調査

第8章 市場分析:地域別

  • 市場シェア(2019年および2027年)
  • 北米
  • 欧州
  • アジア太平洋
  • ラテンアメリカ
  • 中東とアフリカ

第9章 企業プロファイル

  • Abott Molecular
    • 概要
    • 財務
    • 製品のベンチマーク
    • 最近の進展
  • Agendia
  • Boreal Genomics Inc
  • BD Biosciences
  • Caris Life Sciences
  • F. Hoffmann-La Roche Ltd
  • Foundation Medicine
  • Genscript Biotech Corporation
  • Guardant Health, Inc.
  • Helomics Corporation
  • Histogene X
  • Hologic, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Illumina, Inc.
  • Nanostring Technologies, Inc.
  • Neogenomics, Inc.
  • Omniseq
  • Perthera
  • Qiagen N.V.
  • Ribomed Biotechnologies, Inc.
  • Roche Molecular Systems Inc.
  • Sysmex Corporation
  • Tempus Labs
図表

List of Tables

  • Table 1 Global cancer/tumor profiling market (USD Million) 2016 - 2027
  • Table 2 Global cancer/tumor profiling market by region 2016 - 2027 (USD Million)
  • Table 3 Global cancer/tumor profiling market by technology, 2016 - 2027 (USD Million)
  • Table 4 Global cancer/tumor profiling market by cancer type, 2016 - 2027 (USD Million)
  • Table 5 Global cancer/tumor profiling market by biomarker type, 2016 - 2027 (USD Million)
  • Table 6 Global cancer/tumor profiling market by application, 2016 - 2027 (USD Million)
  • Table 7 Immunoassay market, 2016 - 2027 (USD Million)
  • Table 8 Immunoassay market, by region, 2016 - 2027 (USD Million)
  • Table 9 NGS market, 2016 - 2027 (USD Million)
  • Table 10 NGS market, by region, 2016 - 2027 (USD Million)
  • Table 11 PCR market, 2016 - 2027 (USD Million)
  • Table 12 PCR market, by region, 2016 - 2027 (USD Million)
  • Table 13 In Situ Hybridization market, 2016 - 2027 (USD Million)
  • Table 14 In Situ Hybridization market, by region, 2016 - 2027 (USD Million)
  • Table 15 Microarray market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 16 Microarray market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 17 Mass Spectrometry market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 18 Mass Spectrometry market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 19 Other Technology market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 20 Other Technology market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 21 breast cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 22 breast cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 23 lung cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 24 colorectal cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 25 colorectal cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 26 prostate cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 27 prostate cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 28 Melanoma cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 29 melanoma cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 30 other cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 31 other cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 32 genomic biomarkers cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 33 genomic biomarkers cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 34 protein biomarkers cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 35 protein biomarkers cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 36 other biomarkers cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 37 other biomarkers cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 38 Cancer/tumor Profiling market from diagnostics estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 39 Cancer/tumor Profiling from diagnostics market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 40 Cancer/tumor Profiling market from Prognostics estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 41 Cancer/tumor Profiling from Prognostics market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 42 Cancer/tumor Profiling market from Personalized Medicine estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 43 Cancer/tumor Profiling from Personalized Medicine market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 44 Cancer/tumor Profiling market from Biomarker Discovery estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 45 Cancer/tumor Profiling from Biomarker Discovery market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 46 Cancer/tumor Profiling market from Research estimates and forecasts, 2016 - 2027 (USD Million)
  • Table 47 Cancer/tumor Profiling from Research market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • Table 48 North America cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 49 North America cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 50 North America cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 51 U.S. cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 52 U.S. cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 53 U.S. cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 54 Canada cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 55 Canada cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 56 Canada cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 57 Europe cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 58 Europe cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 59 Europe cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 60 UK cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 61 UK cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 62 UK cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 63 Germany cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 64 Germany cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 65 Germany cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 66 France cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 67 France cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 68 France cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 69 Italy cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 70 Italy cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 71 Italy cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 72 Spain cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 73 Spain cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 74 Spain cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 75 Netherlands cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 76 Netherlands cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 77 Netherlands cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 78 Asia Pacific cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 79 Asia Pacific cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 80 Asia Pacific cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 81 China cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 82 China cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 83 China cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 84 India cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 85 India cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 86 India cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 87 Japan cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 88 Japan cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 89 Japan cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 90 South Korea cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 91 South Korea cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 92 South Korea cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 93 Latin America cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 94 Latin America cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 95 Latin America cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 96 Brazil cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 97 Brazil cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 98 Brazil cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 99 Mexico cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 100 Mexico cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 101 Mexico cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 102 Colombia cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 103 Colombia cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 104 Colombia cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 105 MEA cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 106 MEA cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 107 MEA cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 108 Saudi Arabia cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 109 Saudi Arabia cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 110 Saudi Arabia cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 111 South Africa cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 112 South Africa cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 113 South Africa cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 114 Israel cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 115 Israel cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 116 Israel cancer/tumor profiling market by end user (USD Million), 2016 - 2027
  • Table 117 UAE cancer/tumor profiling market by technology (USD Million), 2016 - 2027
  • Table 118 UAE cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
  • Table 119 UAE cancer/tumor profiling market by end user (USD Million), 2016 - 2027

List of Figures

  • FIG 1. Market snapshot
  • FIG 2. Market segmentation & scope
  • FIG 3. Global Cancer/tumor Profiling market size and growth prospects, 2016 - 2027
  • FIG 4. Value chain analysis
  • FIG 5. Cancer/tumor Profiling market dynamics
  • FIG 6. Key market opportunities - prioritized
  • FIG 7. Industry analysis - Porter's
  • FIG 8. PESTEL analysis
  • FIG 9. Global Cancer/tumor Profiling market share by technology, 2019 & 2027
  • FIG 10. Global Cancer/tumor Profiling market share by cancer type, 2019 & 2027
  • FIG 11. Global Cancer/tumor Profiling market share by biomarker type, 2019 & 2027
  • FIG 12. Global Cancer/tumor Profiling market share by application, 2019 & 2027
  • FIG 13. Global Cancer/tumor Profiling market share by region, 2019 & 2027
  • FIG 14. Competitive environment
  • FIG 15. Strategy framework
目次
Product Code: PM1713

Title:
Cancer/Tumor Profiling Market Share, Size, Trends, Industry Analysis Report by Technology (Immunoassay, NGS, PCR, In Situ Hybridization, Microarray, Mass Spectrometry, Others); By Biomarker Type (Genomic Biomarkers, Protein Biomarkers, Others); By Cancer Type; By Application; By Regions - Segment Forecast, 2020 - 2027.

The global cancer/tumor profiling market size is expected to reach USD 15.32 billion by 2027 according to a new study by Polaris Market Research. The report "Cancer/Tumor Profiling Market Share, Size, Trends, Industry Analysis Report by Technology (Immunoassay, NGS, PCR, In Situ Hybridization, Microarray, Mass Spectrometry, Others); By Cancer Type (Breast, Lung, Colorectal, Prostate, Melanoma, Others); By Biomarker Type (Genomic Biomarkers, Protein Biomarkers, Others); By Application (Personalized Medicine, Diagnostics, Prognostics, Biomarker Discovery, Research); By Regions - Segment - Forecast, 2020 - 2027" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing demand for tumor profiling and diagnosis and therapy techniques is driven by oncologists. Increased use of biomarkers in tumor profiling and increasing use of next-generation cancer profiling sequencing methods are some of the main factors driving the growth of the tumor profiling market. Tumor profiling is used to evaluate the metabolism, properties, and mutations of the tumor that can assist discover effective therapies. Drugs that target these mutated kinases can be discovered and developed based on genetic modification. The profiling is considered a requirement to increase the sensitivity of kinases-focused medications because they rely on individual tumors genetic composition. Thus, these mutated profiles of DNA tumors help to create specific anticarcinogenic treatments.

Globally there is a rise in cancer patients every year. According to the WHO this disease is considered to be the second leading cause mortalities in the year 2019. It is also estimated that that 1 out of 6 deaths were due to cancer. WHO has marked that one third of deaths from this disease are due to 5 leading behavioral and dietary risks. The factors include high body mass index, low fruit and vegetable intake, lack of physical activity, tobacco use, and alcohol use. Tobacco is one of the leading factors for the rise in the prevalence of cancer and mortalities that approximately 22%. According to WHO, in 2015, there were around 17.6 million cases related to cancer that increases to 18.1 million cases in 2018 and nearly 9.6 million mortalities. The rising number of patients is the major factor for the growth of global cancer/tumor profiling market.

Certified techniques have been identified that can reduce the time taken to identify tumors and stages of advancement along with improved support for cancer research. Moreover, major investments by major biotechnology companies for the development of new therapies and new techniques of drug design are being witnessed across countries. This has significantly driven market growth and is expected to sustain growth during the forecast period. Biomarkers play a significant part in the design of a drug regime for cancer patients by quickly developing gene profiling techniques and individualizing targeted therapies. Currently, genome based prognostic biomarkers can be used to prognosticate multiple kinds of cancer in the clinical phases. Researchers, however, contend that conversion difficulties are hindering the broad divide between the phase of biomarker discovery and their clinical conversion. The acquisition of tumor genomic data is seen as the most significant step in cancer prediction, diagnosis, and therapy.

Next Generation Sequencing (NGS) is a sophisticated technique for the sequence that can be used for accurate tumor DNA genomic sequencing. The interpreted data contribute much more quickly to the assessment of tumor purity and the magnitude of disease progression. The primary benefit of NGS is the complete exotic sequence which helps examine all protein-coding areas of the human genome. It also enables whole genome sequencing to be useful for analysis of protein coding and non-coding areas in the human genome. Such advances in technology are one of the primary drivers of global cancer/tumor profiling market.

Moreover, the growing demand for personalized medicine further provides substantial opportunities for the tumor profiling market. The personalized medicine is defined as typical care in the treatment that is customized as per an individual patient. There have been several types of research going on presently to develop personal medicine based on the patients. Several factors should be considered before providing personal medicine to a patient. Firstly, the doctors have to detect the type or the symptoms of cancer that can be developed in a patient. Detection is important for the surgeon or the doctor, to find the best suited therapy that can treat the person. For developing a personalized medicine tumor profiling need to be taken into account as these tests will eventually reveal the various conditions of the patients such as detection of the individual developing a specific type of disease.

Polaris Market research has segmented the cancer tumor/profiling market on the basis of:

Cancer Tumor/Profiling Technology Outlook (Revenue, USD Million, 2016 - 2027)

  • Immunoassay
  • NGS
  • PCR
  • In Situ Hybridization
  • Microarray
  • Mass Spectrometry
  • Others

Cancer Tumor/Profiling Cancer Type Outlook (Revenue, USD Billion, 2016 - 2027)

  • Breast
  • Lung
  • Colorectal
  • Prostate
  • Melanoma
  • Others

Cancer Tumor/Profiling Biomarker Type Outlook (Revenue, USD Billion, 2016 - 2027)

  • Genomic Biomarkers
  • Protein Biomarkers
  • Others

Cancer Tumor/Profiling Application Outlook (Revenue, USD Billion, 2016 - 2027)

  • Personalized Medicine
  • Diagnostics
  • Prognostics
  • Biomarker Discovery
  • Research

Cancer Tumor/Profiling Regional Outlook (Revenue, USD Million, 2016 - 2027)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
  • Asia Pacific
    • India
    • Japan
    • China
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Colombia
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Israel
    • UAE

Table of Contents

1. Overview and Scope

  • 1.1. Research goal & scope
  • 1.2. Research assumptions
  • 1.3. Research Methodology
    • 1.3.1. Primary data sources
    • 1.3.2. Secondary data sources
  • 1.4. Key take-aways
  • 1.5. Stakeholders

2. Executive Summary

  • 2.1. Market Definition
  • 2.2. Market Segmentation

3. Cancer/tumor Profiling Market Insights

  • 3.1. Cancer/tumor Profiling- Industry snapshot
  • 3.2. Cancer/tumor Profiling market dynamics
    • 3.2.1. Cancer/tumor Profiling- Market Forces
      • 3.2.1.1. Cancer/tumor Profiling Market driver analysis
      • 3.2.1.2. Cancer/tumor Profiling Market restraint/challenges analysis
      • 3.2.1.3. Cancer/tumor Profiling Market opportunity analysis
  • 3.3. Industry analysis - Porter's five force
    • 3.3.1. Bargaining power of supplier
    • 3.3.2. Bargaining power of buyer
    • 3.3.3. Threat of substitute
    • 3.3.4. Threat of new entrant
    • 3.3.5. Degree of competition
  • 3.4. Cancer/tumor Profiling market PEST analysis
  • 3.5. Value Chain Analysis
  • 3.6. Competitive Ranking Analysis, 2019

4. Cancer/tumor Profiling Market Size and Forecast by Transducer Frequency Range

  • 4.1. Global Cancer/tumor Profiling market share by technology, 2019 & 2027
  • 4.2. Immunoassay
    • 4.2.1. Global Immunoassay market estimates and forecasts, 2016 - 2027 (USD Million)
    • 4.2.2. Global Immunoassay market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 4.3. Next Generation Sequencing (NGS)
    • 4.3.1. Global NGS market estimates and forecasts, 2016 - 2027 (USD Million)
    • 4.3.2. Global NGS market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 4.4. Polymerase Chain Reaction (PCR)
    • 4.4.1. Global PCR market estimates and forecasts, 2016 - 2027 (USD Million)
    • 4.4.2. Global PCR market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 4.5. In Situ Hybridization
    • 4.5.1. Global In Situ Hybridization market estimates and forecasts, 2016 - 2027 (USD Million)
    • 4.5.2. Global In Situ Hybridization market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 4.6. Microarray
    • 4.6.1. Global Microarray market estimates and forecasts, 2016 - 2027 (USD Million)
    • 4.6.2. Global Microarray market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 4.7. Mass Spectrometry
    • 4.7.1. Global Mass Spectrometry market estimates and forecasts, 2016 - 2027 (USD Million)
    • 4.7.2. Global Mass Spectrometry market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 4.8. Other Technology
    • 4.8.1. Global Other Technology market estimates and forecasts, 2016 - 2027 (USD Million)
    • 4.8.2. Global Other Technology market estimates and forecasts, by region, 2016 - 2027 (USD Million)

5. Cancer/tumor Profiling Market Size and Forecast by Cancer Type

  • 5.1. Global Cancer/tumor Profiling market share by cancer type, 2019 & 2027
  • 5.2. Breast Cancer
    • 5.2.1. Global breast cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.2.2. Global breast cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 5.3. Lung Cancer
    • 5.3.1. Global lung cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.3.2. Global lung cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 5.4. Colorectal Cancer
    • 5.4.1. Global colorectal cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.4.2. Global colorectal cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 5.5. Prostate Cancer
    • 5.5.1. Global prostate cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.5.2. Global prostate cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 5.6. Melanoma Cancer
    • 5.6.1. Global Melanoma cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.6.2. Global melanoma cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 5.7. Other Cancer
    • 5.7.1. Global other cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
    • 5.7.2. Global other cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)

6. Cancer/tumor Profiling Market Size and Forecast by Biomarker Type

  • 6.1. Global Cancer/tumor Profiling market share by biomarker type, 2019 & 2027
  • 6.2. Genomic Biomarkers
    • 6.2.1. Global genomic biomarkers cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
    • 6.2.2. Global genomic biomarkers cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 6.3. Protein Biomarkers
    • 6.3.1. Global protein biomarkers cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
    • 6.3.2. Global protein biomarkers cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 6.4. Other Biomarkers
    • 6.4.1. Global other biomarkers cancer/tumor profiling market estimates and forecasts, 2016 - 2027 (USD Million)
    • 6.4.2. Global other biomarkers cancer/tumor profiling market estimates and forecasts, by region, 2016 - 2027 (USD Million)

7. Cancer/tumor Profiling Market Size and Forecast by Application

  • 7.1. Global Cancer/tumor Profiling market share by application, 2019 & 2027
  • 7.2. Diagnostics
    • 7.2.1. Global Cancer/tumor Profiling market from diagnostics estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.2.2. Global Cancer/tumor Profiling from diagnostics market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 7.3. Prognostics
    • 7.3.1. Global Cancer/tumor Profiling market from Prognostics estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.3.2. Global hard Cancer/tumor Profiling from Prognostics market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 7.4. Personalized Medicine
    • 7.4.1. Global Cancer/tumor Profiling market from Personalized Medicine estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.4.2. Global hard Cancer/tumor Profiling from Personalized Medicine market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 7.5. Biomarker Discovery
    • 7.5.1. Global Cancer/tumor Profiling market from Biomarker Discovery estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.5.2. Global hard Cancer/tumor Profiling from Biomarker Discovery market estimates and forecasts, by region, 2016 - 2027 (USD Million)
  • 7.6. Research
    • 7.6.1. Global Cancer/tumor Profiling market from Research estimates and forecasts, 2016 - 2027 (USD Million)
    • 7.6.2. Global hard Cancer/tumor Profiling from Research market estimates and forecasts, by region, 2016 - 2027 (USD Million)

8. Cancer/tumor Profiling Market Size and Forecast by Region

  • 8.1. Global cancer/tumor profiling market share by region, 2019 & 2027
  • 8.2. North America
    • 8.2.1. North America cancer/tumor profiling market by technology (USD Million), 2016 - 2027
    • 8.2.2. North America cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
    • 8.2.3. North America cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
    • 8.2.4. North America cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.2.5. U.S.
      • 8.2.5.1. U.S. cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.2.5.2. U.S. cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.2.5.3. U.S. cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.2.5.4. U.S. cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.2.6. Canada
      • 8.2.6.1. Canada cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.2.6.2. Canada cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.2.6.3. Canada cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.2.6.4. Canada cancer/tumor profiling market by application (USD Million), 2016 - 2027
  • 8.3. Europe
    • 8.3.1. Europe cancer/tumor profiling market by technology (USD Million), 2016 - 2027
    • 8.3.2. Europe cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
    • 8.3.3. Europe cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
    • 8.3.4. Europe cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.3.5. Germany
      • 8.3.5.1. Germany cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.3.5.2. Germany cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.3.5.3. Germany cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.3.5.4. Germany cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.3.6. UK
      • 8.3.6.1. UK cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.3.6.2. UK cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.3.6.3. UK cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.3.6.4. UK cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.3.7. France
      • 8.3.7.1. France cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.3.7.2. France cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.3.7.3. France cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.3.7.4. France cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.3.8. Italy
      • 8.3.8.1. Ital cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.3.8.2. Italy cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.3.8.3. Italy cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.3.8.4. Italy cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.3.9. Spain
      • 8.3.9.1. Spain cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.3.9.2. Spain cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.3.9.3. Spain cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.3.9.4. Spain cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.3.10. Netherlands
      • 8.3.10.1. Netherlands cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.3.10.2. Netherlands cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.3.10.3. Netherlands cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.3.10.4. Netherlands cancer/tumor profiling market by application (USD Million), 2016 - 2027
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific cancer/tumor profiling market by technology (USD Million), 2016 - 2027
    • 8.4.2. Asia Pacific cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
    • 8.4.3. Asia Pacific cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
    • 8.4.4. Asia Pacific cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.4.5. China
      • 8.4.5.1. China cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.4.5.2. China cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.4.5.3. China cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.4.5.4. China cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.4.6. South Korea
      • 8.4.6.1. South Korea cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.4.6.2. South Korea cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.4.6.3. South Korea cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.4.6.4. South Korea cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.4.7. Japan
      • 8.4.7.1. Japan cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.4.7.2. Japan cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.4.7.3. Japan cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.4.7.4. Japan cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.4.8. India
      • 8.4.8.1. India cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.4.8.2. India cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.4.8.3. India cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.4.8.4. India cancer/tumor profiling market by application (USD Million), 2016 - 2027
  • 8.5. Latin America
    • 8.5.1. Latin America cancer/tumor profiling market by technology (USD Million), 2016 - 2027
    • 8.5.2. Latin America cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
    • 8.5.3. Latin America cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
    • 8.5.4. Latin America cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.5.5. Brazil
      • 8.5.5.1. Brazil cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.5.5.2. Brazil cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.5.5.3. Brazil cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.5.5.4. Brazil cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.5.6. Mexico
      • 8.5.6.1. Mexico cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.5.6.2. Mexico cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.5.6.3. Mexico cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.5.6.4. Mexico cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.5.7. Colombia
      • 8.5.7.1. Colombia cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.5.7.2. Colombia cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.5.7.3. Colombia cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.5.7.4. Colombia cancer/tumor profiling market by application (USD Million), 2016 - 2027
  • 8.6. Middle East & Africa
    • 8.6.1. MEA cancer/tumor profiling market by technology (USD Million), 2016 - 2027
    • 8.6.2. MEA cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
    • 8.6.3. MEA cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
    • 8.6.4. MEA cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.6.5. Saudi Arabia
      • 8.6.5.1. Saudi Arabia cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.6.5.2. Saudi Arabia cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.6.5.3. Saudi Arabia cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.6.5.4. Saudi Arabia cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.6.6. South Africa
      • 8.6.6.1. South Africa cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.6.6.2. South Africa cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.6.6.3. South Africa cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.6.6.4. South Africa cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.6.7. Israel
      • 8.6.7.1. Israel cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.6.7.2. Israel cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.6.7.3. Israel cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.6.7.4. Israel cancer/tumor profiling market by application (USD Million), 2016 - 2027
    • 8.6.8. UAE
      • 8.6.8.1. UAE cancer/tumor profiling market by technology (USD Million), 2016 - 2027
      • 8.6.8.2. UAE cancer/tumor profiling market by cancer type (USD Million), 2016 - 2027
      • 8.6.8.3. UAE cancer/tumor profiling market by biomarker type (USD Million), 2016 - 2027
      • 8.6.8.4. UAE cancer/tumor profiling market by application (USD Million), 2016 - 2027

9. Company Profiles

  • 9.1. Abott Molecular
    • 9.1.1. Overview
    • 9.1.2. Financials
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Developments
  • 9.2. Agendia
    • 9.2.1. Overview
    • 9.2.2. Financials
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Developments
  • 9.3. Boreal Genomics Inc
    • 9.3.1. Overview
    • 9.3.2. Financials
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Developments
  • 9.4. BD Biosciences
    • 9.4.1. Overview
    • 9.4.2. Financials
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Developments
  • 9.5. Caris Life Sciences
    • 9.5.1. Overview
    • 9.5.2. Financials
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Developments
  • 9.6. F. Hoffmann-La Roche Ltd
    • 9.6.1. Overview
    • 9.6.2. Financials
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Developments
  • 9.7. Foundation Medicine
    • 9.7.1. Overview
    • 9.7.2. Financials
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Developments
  • 9.8. Genscript Biotech Corporation
    • 9.8.1. Overview
    • 9.8.2. Financials
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Developments
  • 9.9. Guardant Health, Inc.
    • 9.9.1. Overview
    • 9.9.2. Financials
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Developments
  • 9.10. Helomics Corporation
    • 9.10.1. Overview
    • 9.10.2. Financials
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Developments
  • 9.11. Histogene X
    • 9.11.1. Overview
    • 9.11.2. Financials
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Developments
  • 9.12. Hologic, Inc.
    • 9.12.1. Overview
    • 9.12.2. Financials
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Developments
  • 9.13. HTG Molecular Diagnostics, Inc.
    • 9.13.1. Overview
    • 9.13.2. Financials
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Developments
  • 9.14. Illumina, Inc.
    • 9.14.1. Overview
    • 9.14.2. Financials
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Developments
  • 9.15. Nanostring Technologies, Inc.
    • 9.15.1. Overview
    • 9.15.2. Financials
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Developments
  • 9.16. Neogenomics, Inc.
    • 9.16.1. Overview
    • 9.16.2. Financials
    • 9.16.3. Product Benchmarking
    • 9.16.4. Recent Developments
  • 9.17. Omniseq
    • 9.17.1. Overview
    • 9.17.2. Financials
    • 9.17.3. Product Benchmarking
    • 9.17.4. Recent Developments
  • 9.18. Perthera
    • 9.18.1. Overview
    • 9.18.2. Financials
    • 9.18.3. Product Benchmarking
    • 9.18.4. Recent Developments
  • 9.19. Qiagen N.V.
    • 9.19.1. Overview
    • 9.19.2. Financials
    • 9.19.3. Product Benchmarking
    • 9.19.4. Recent Developments
  • 9.20. Ribomed Biotechnologies, Inc.
    • 9.20.1. Overview
    • 9.20.2. Financials
    • 9.20.3. Product Benchmarking
    • 9.20.4. Recent Developments
  • 9.21. Roche Molecular Systems Inc.
    • 9.21.1. Overview
    • 9.21.2. Financials
    • 9.21.3. Product Benchmarking
    • 9.21.4. Recent Developments
  • 9.22. Sysmex Corporation
    • 9.22.1. Overview
    • 9.22.2. Financials
    • 9.22.3. Product Benchmarking
    • 9.22.4. Recent Developments
  • 9.23. Tempus Labs
    • 9.23.1. Overview
    • 9.23.2. Financials
    • 9.23.3. Product Benchmarking
    • 9.23.4. Recent Developments
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.